Precision Clinical Research LLC

1. Moderna TX, Inc. $4,143,905 356 payments
2. Regeneron Pharmaceuticals, Inc. $2,925,424 102 payments
3. Eli Lilly and Company $1,396,730 34 payments
4. AbbVie, Inc. $913,078 188 payments
5. Novartis Pharmaceuticals Corporation $827,012 13 payments
6. Pfizer Inc. $230,721 56 payments
7. Allergan Inc. $190,171 30 payments
8. VYNE Pharmaceuticals Inc. $46,996 10 payments
9. ACADIA Pharmaceuticals Inc $31,449 7 payments
10. Evofem Biosciences, Inc. $23,854 11 payments

1. A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity $2,906,356 96 payments
2. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $2,357,387 37 payments
3. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $1,185,497 258 payments
4. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity $753,531 3 payments
5. A Randomized, Four-Arm, Placebo-Controlled, Participant, Investigator and Sponsor-Blinded Study Investigating the Safety, Tolerability and Efficacy of Intra-Articular Canakinumab Followed By Intra-Articular Lna043 in Patients With Knee Osteoarthritis $526,383 5 payments
6. M16-283 $318,129 42 payments
7. A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 $277,390 20 payments
8. A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy $274,026 5 payments
9. M16-011 $245,079 15 payments
10. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease $218,692 9 payments

1. Professional salary support $20,719 10 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.